After G‐CSF administration, threshold scores were slightly enhanced in both myeloma patients (8.9 ± 3.6 vs. 9.3 ± 3.3) and allogeneic stem cell donors (10.2 ± 3.5 vs. 11.8 ± 2.9). The gene discussed is CSF3; the disease is plasma cell myeloma.